Search clinical trials for: beta-II-agonist, inhale steroid

Total 4769 results

Mercy Research
Forest Laboratories

Completed

Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function

Hypertension

United States
Astellas Pharma Inc

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder

Urinary Bladder, Overactive

Japan
Mylan Bertek Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension

Hypertension

United States
Boehringer Ingelheim

Completed

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Pulmonary Disease, Chronic Obstructive

United States
Imperial College London
AstraZeneca

Completed

Effect of Symbicort on GR Localisation in Asthma

Asthma

United Kingdom
De Motu Cordis
Novotech (Australia) Pty Limited

Completed

Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults

Anaphylactic Reaction

Australia
Henning Bundgaard
Hvidovre University Hospital; Herlev Hospital; Royal North Shore Hospital; Bispebjerg-Frederiksberg... and other collaborators

Completed

Beta 3 Agonist Treatment in Heart Failure-2 (BEAT-HF II)

Heart Failure With Reduced Ejection Fraction NYHA Class III-IV

Denmark
Far Eastern Memorial Hospital

Withdrawn

Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome

Overactive Bladder Syndrome

Taiwan
GlaxoSmithKline

Completed

Regulatory Nebilet PMS (Nebilet PMS)

Heart Failure | Hypertension

Korea, Republic of
Seoul National University Hospital

Unknown

MIrabegron With oveRACtive bLadder Symptoms in mEn

Overactive Bladder

Korea, Republic of
AstraZeneca

Completed

Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men (AZD3199MAD)

Healthy Volunteers

Sweden
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Overactive Bladder

Poland, United Kingdom, Germany, Spain, Netherlands, Belgium, Czech Republic, Italy, Norway, Hungary, Sweden, Denmark, Greece, France, Russian Federation
Astellas Pharma Inc

Completed

Study of the Effect of Food on the Pharmacokinetics of Mirabegron

Healthy | Pharmacokinetics of Mirabegron

United States
Mylan Bertek Pharmaceuticals

Completed

A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients

Hypertension

United States
National Institute of Mental Health (NIMH)

Recruiting

Effects of an ER Beta Agonist (Lilly Compound LY500307) on Estradiol-Withdrawal-Induced Mood Symptoms in Women With Past Perimenopausal Depression

Perimenopause-Related Depression

United States
Theodore R. Brown, MD MPH
Astellas Pharma Inc

Completed

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis (MIRROR)

Multiple Sclerosis

United States
Baylor College of Medicine

Completed

Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain

Ureteral Obstruction | Flank Pain

United States
Assistance Publique - Hôpitaux de Paris
Association Française contre les Myopathies (AFM), Paris

Completed

Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy (NEBIDYS)

Heart Failure | Duchenne Muscular Dystrophy | Cardiomyopathy

France
University of California, San Diego
Forest Laboratories

Completed

Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension

Hypertension | Pre-hypertension

United States
Buddhist Tzu Chi General Hospital

Completed

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Urinary Incontinence | Overactive Bladder Syndrome
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Completed

A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Taiwan
Astellas Pharma Inc

Completed

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Healthy Subjects | Plasma Concentration of Mirabegron

Japan
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Withdrawn

Electronic Cigarettes or Nicotine Inhaler for Smoking Cessation

Tobacco Use Disorder

United States
Astellas Pharma Inc

Completed

Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
Otto Muzik

Unknown

Efficacy of Pharmacological Stimulation of BAT and WAT in Lean and Obese Young Adults (MiraBAT)

Brown Fat

United States
Astellas Pharma Inc

Completed

A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Japan
AstraZeneca

Completed

Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma

Asthma

Sweden
Jagiellonian University
University Hospital in Krakow

Not yet recruiting

Beta-blockade in Unruptured Intracranial Aneurysm (BBLURAN)

Intracranial Aneurysm

Poland
Philip Kern
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Mechanisms for Activation of Beige Adipose Tissue in Humans

PreDiabetes

United States
Astellas Pharma China, Inc.

Completed

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

Urge Incontinence | Overactive Bladder (OAB)

China
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Astellas Pharma Global Development, Inc.

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PILLAR)

Overactive Bladder (OAB)

United States, Canada
Philadelphia Urosurgical Associates
Astellas Pharma Global Development, Inc.

Terminated

A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis (MirabegronIC)

Cystitis, Interstitial

United States
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (ARIES)

Urinary Bladder, Overactive

United States, Canada
Astellas Pharma Inc

Completed

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (CAPRICORN)

Urinary Bladder, Overactive

United States, Hungary, Canada, Spain, Finland, Slovakia, Czechia, Sweden, Germany, Denmark, Norway
Massachusetts General Hospital
Forest Laboratories

Completed

Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease (NIRVANA)

Microvascular Angina

United States
Astellas Pharma Inc

Completed

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Lower Urinary Tract Symptoms | Bladder Outlet Obstruction

United States, Canada
Astellas Pharma Inc

Completed

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

United States
Université de Sherbrooke
Laval University

Completed

Activation of Brown Adipose Tissue Metabolism Using Mirabegron (GB9)

Type 2 Diabetes

Canada
Forest Laboratories
Mylan Laboratories

Terminated

Study to Evaluate Symptoms in Patients Treated With Nebivolol or Metoprolol Extended-release (ER) for Hypertension

Hypertension

United States
Mylan Bertek Pharmaceuticals

Completed

Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans

Hypertension

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Persistent Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Asthma

United States
University of California, San Diego

Recruiting

ADRB3 Signaling Pathway in Human Adipose Tissue

Obesity, Prediabetes

United States
Ain Shams University

Recruiting

Evaluating the Outcome of Cardio Selective beta1- Blockers Use in Patients With Copd

Copd

Egypt
National Taiwan University Hospital

Completed

Predictors for Retreatement of OAB After DC Mirabegron

Recurrence of Overactive Bladder Syndrome

Taiwan
Astellas Pharma Inc

Completed

Long-Term Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
Forest Laboratories

Completed

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Stage 2 Hypertension | Stage 1 Hypertension

United States
AstraZeneca

Completed

To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart

Chronic Obstructive Pulmonary Disease | Lung Disease

United Kingdom
Clinical Hospital Center Zemun

Withdrawn

Echocardiographic Study of a Single Dose Bisoprolol Versus Nebivolol in Healthy Subjects (BINEB)

Bisoprolol Adverse Reaction | Nebivolol Adverse Reaction

Serbia

3

Subscribe